retatrutide weight loss clinical trials retatrutide A New Obesity Drug Delivered Surgery-Level in Retatrutide, an investigational triple hormone

More patients reach glycemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: a post hoc time-to-control analysis of LixiLan-O and LixiLan-L

These compounded versions are not FDA-approved, and the FDA has expressed concerns about dosing errors, quality issues, and even fraudulent products

watch now India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20

The GLP-1RAs, particularly semaglutide, are now used on a global scale for diabetes and obesity, and emerging pharmacovigilance reports suggest that some patients may experience oral and salivary symptoms during therapy, including xerostomia, dysgeusia, oral hypoesthesia, and throat discomfort [1]

Among those who have used GLP-1 drugs, about half report they have experienced nausea and about one-third experienced diarrhea the two most-common side effects associated with the medications